{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"56.4","upperLimit":"82.0","value":"70.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"}],"units":"Participants"}],"description":"MRDnegative Complete Response (CR) per the IMWHG criteria is defined as absence of phenotypically aberrant clonal plasma cells by flow cytometry on bone marrow aspirates using the eight-color two tube approach with a minimum sensitivity of 1 in 10\\^5 nucleated cells or higher.","dispersionType":"95% Confidence Interval","groups":[{"description":"Carfilzomib (intravenous (IV), Days 1, 2, 8, 9, 15, and 16 of the 28-day cycle); Revlimid (by mouth (PO), Days 1-21 of the 28-day cycle; exception: not given on cycle 1 day 1); and Dexamethasone (PO or IV, Days 1, 2, 8, 9, 15, 16, 22, and 23 of the 28-day cycle; exception: not given on cycle 1 day 1)\n\nCarfilzomib intravenous (IV) 20-36 mg/m\\^2 per dose on days 1, 2, 8, 9, 15, and 16 of each cycle based on arm; until disease progression or unacceptable toxicity.\n\nRevlimid by mouth (PO) 25 mg/day, days 1-21 every 28 days of each cycle based on arm; until disease progression or unacceptable toxicity.","id":"OG000","title":"All Participants"}],"paramType":"NUMBER","populationDescription":"54/55 participants are evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"8 months","title":"Percentage of Participants With Minimal Residual Disease (MRD)Negative Complete Response (CR) Per International Myeloma Working Group (IMWG) Criteria","type":"PRIMARY","unitOfMeasure":"percentage of participants"}